2, 3, 4', 5-tetrahydroxystilbene-2-0-β-d Glycoside Attenuates Age- and Diet-Associated Non-Alcoholic Steatohepatitis and Atherosclerosis in LDL Receptor Knockout Mice and Its Possible Mechanisms.

Abstract

The compound, 2,3,5,4'-tetrahydroxystilbene-2-O-β-d-glucoside (TSG), a primary bioactive polyphenolic component of Polygonum multiflorum exerts numerous pharmacological activities. However, its protective effect against non-alcoholic steatohepatitis (NASH), in the context of metabolic syndrome, remains poorly understood. The aim of the present study is to evaluate the effects of TSG treatment on middle-aged (12-mo-old) male LDLr-/- mice, which were fed a high fat diet for 12 weeks to induce metabolic syndrome and NASH. At the end of the experiment, the blood samples of mice were collected for determination of metabolic parameters. Liver and aorta tissues were collected for analysis, such as histology, immunofluorescence, hepatic lipid content, real-time PCR, and western blot. Our data show that TSG treatment improved the different aspects of NASH (steatosis, inflammation, and fibrosis) and atherosclerosis, as well as some of the metabolic basal characteristics. These modulatory effects of TSG are mediated, at least in part, through regulating key regulators of lipid metabolism (SREBP1c, PPARα and their target genes, ABCG5 and CYP7A1), inflammation (CD68, TNF-α, IL-6 and ICAM), fibrosis (α-SMA and TNFβ) and oxidative stress (NADPH-oxidase 2/4, CYP2E1 and antioxidant enzymes). These results suggest that TSG may be a promising candidate for preventing and treating the progression of NASH.

• Authors: Jin Xu, Yi Peng, Yi Zeng, Yi-Qiao Hua, Xiao-le Xu
• Journal: International journal of molecular sciences (Int J Mol Sci) Vol. 20 Issue 7 (Apr 01 2019) ISSN: 1422-0067 [Electronic] Switzerland
• PMID: 30939745 (Publication Type: Journal Article)

Chemical References

• Glucosides
• Receptors, LDL
• Stilbenes
• 2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside

Topics

• Aging (pathology)
• Animals
• Aorta (drug effects, metabolism)
• Atherosclerosis (drug therapy, etiology)
• Diet, High-Fat (adverse effects)
• Glucosides (pharmacology, therapeutic use)
• Lipid Metabolism
• Liver (drug effects, metabolism)
• Male
• Mice
• Mice, Inbred C57BL
• Non-alcoholic Fatty Liver Disease (drug therapy, etiology)
• Receptors, LDL (genetics)
• Stilbenes (pharmacology, therapeutic use)